An efficacy and mechanism evaluation study of Levosimendan for the Prevention of Acute oRgan Dysfunction in Sepsis (LeoPARDS)
Phase of Trial: Phase II
Latest Information Update: 18 Jun 2019
Price : $35 *
At a glance
- Drugs Levosimendan (Primary)
- Indications Sepsis
- Focus Therapeutic Use
- Acronyms LeoPARDS
- 10 Nov 2016 According to Tenax Therapeutics media release, in October, company presented initial results at the 29th European Society of Intensive Care Medicine (ESICM) Annual Congress.
- 01 Nov 2016 Status changed from active, no longer recruiting to completed.
- 05 Oct 2016 Primary endpoint has not been met, (Mean sequential organ failure assessment (SOFA) score), according to the results published.